Open AccessProtective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model
Author(s) -
Bégué Rodolfo E.,
SadowskaKrowicka Halina
Publication year - 2010
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2010.00726.x
Subject(s) - adjuvant , immunogenicity , recombinant dna , helicobacter pylori , nasal administration , microbiology and biotechnology , antigen , cpg oligodeoxynucleotide , hydroxide , immunology , medicine , biology , chemistry , biochemistry , gene expression , dna methylation , organic chemistry , gene
Efforts are underway for the development of an effective vaccine against Helicobacter pylori infection. We prepared recombinant full‐length (568 aa) H. pylori recombinant urease B (rUreB) protein and tested it for immunogenicity and protection. BALB/c mice received either rUreB (40 μg) plus CpG (10 μg) intranasally, rUreB (50 μg) plus 3% aluminum hydroxide (50 μL) intramuscularly or rUreB (25 μg) plus Freund's adjuvant (25 μL) subcutaneously, three times (weeks 0, 2 and 6). Intranasal rUreB plus CpG was neither immunogenic nor protective; intramuscular rUreB plus aluminum hydroxide was immunogenic and modestly protective, and subcutaneous rUreB plus Freund's adjuvant was immunogenic and highly protective. The fact that protection was improved with Freund's adjuvant indicates that rUreB is a good antigen for a vaccine but that it needs a stronger adjuvant than aluminum hydroxide.